Century Therapeutics Inc
Century Therapeutics Inc (IPSC) Historical Volatility
IPSC's 30 day historical volatility is 110.12%, in the 84th percentile of readings over the past year. This is a high percentile, meaning Century Therapeutics Inc shares have swung far more than usual. IPSC's 30 day implied volatility sits at 250.68%, with an IV Rank of 55.56%, leaving IV 140.56 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 20, 2026.
Read more
Tracking IPSC historical volatility helps you see how much Century Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, IPSC's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor IPSC 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. IPSC's 30 day historical volatility, or IPSC HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing IPSC's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 20, 2026
As of Nov 20, 2026
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →